Published June 27, 2024
| Version v1
Journal article
Open
Quality of life of patients with cardiomyopathy treated with sacubitril/valsartan vs. standard therapy during or after COVID-19 in Kazakhstan
Authors/Creators
- 1. NPJSC "S. D. Asfendiyarov Kazakh National Medical University", Almati, Kazakhstan
- 2. Medical University – Sofia, Sofia, Bulgaria
Description
The objective of this study is to evaluate the quality of life (QoL) of hospitalised patients with cardiomyopathy (CM) treated with a fixed dose combination (FDC) of sacubitril/valsartan, or standard therapy in Kazakhstan during or after COVID-19.
This is an observational study of patients with incidents of CM that require hospitalisation during or after a COVID-19 infection. QoL was evaluated with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) during admission. Demographic and other characteristics of the patients were analysed for both patient groups: on standard therapy and on FDC therapy with sacubitril/valsartan.
Patients on standard therapy tended to be older and had a higher relative share of previous cardiac surgery. The vaccination rate is low in general and was lower in the group on standard therapy. The QoL between the two groups was significantly higher in the group on FDC therapy. No statistically significant difference in the QoL between males and females was found. The vaccination status also does not influence the QoL. Patients with prior surgery possess a higher quality of life. QoL in younger patients is higher. There is a statistically significant negative correlation between age and QoL, and with the increase in age over one year, the quality of life will decrease by 0.3622 points.
Sacubitril/valsartan is associated with higher QoL in hospitalised patients with CM during or after COVID-19. QoL is correlated with age. Vaccination does not affect QoL, but patients with prior cardiac surgeries possess a higher QoL.
Files
PHAR_article_125055.pdf
Files
(291.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:a2493934e9a90d8f49c2504bd79c651b
|
216.7 kB | Preview Download |
|
md5:011c884de182274681cff6fad78906af
|
74.3 kB | Preview Download |
Additional details
References
- Arnold SV, Spertus JA, Lei Y, Allen KB, Chhatriwalla AK, Leon MB, Smith CR, Reynolds MR, Webb JG, Svensson LG, Cohen DJ (2013) Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circulation: Heart Failure 6(1): 61–67. https://doi.org/10.1161/CIRCHEARTFAILURE.112.970053
- Campal R, Del Castillo H, Arroyo Rivera B, de Juan Bitriá C, Taibo Urquia M, Sánchez Borque P, Miracle Blanco Á, Bravo Calero L, Martí Sánchez D, Tuñón Fernández J (2021) Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/ Angiotensin) registry. Cardiology Journal 28(3): 402–410. https://doi.org/10.5603/CJ.a2021.0009
- CDC [Centers for Disease Control and Prevention] (2023) People who are at higher risk for severe illness. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html
- Chandra A, Polanczyk CA, Claggett BL, Vaduganathan M, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Schwende H, Zile MR, Desai AS, Pfeffer MA, McMurray JJV, Solomon SD, Lewis EF (2022) Health-related quality of life outcomes in PARAGON-HF. European Journal of Heart Failure 24(12): 2264–2274. https://doi.org/10.1002/ejhf.2738
- Ciarambino Т, Menna G, Sansone G, Giordano M (2021) Cardiomyopathies: An Overview. International Journal of Molecular Sciences 22(14): 7722. https://doi.org/10.3390/ijms22147722
- Cooper L, McKenna W, Dardas T (2023) Definition and classification of the cardiomyopathies. UpToDate. https://www.uptodate.com/contents/definition-and-classification-of-the-cardiomyopathies?source=mostViewed_widget
- Cowger JA, Naka Y, Aaronson KD, Horstmanshof D, Gulati S, Rinde-Hoffman D, Pinney S, Adatya S, Farrar DJ, Jorde UP (2018) MOMENTUM 3 Investigators. Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: A call for new metrics for left ventricular assist device patients. The Journal of Heart and Lung Transplantation 37(1): 15–24. https://doi.org/10.1016/j.healun.2017.10.019
- Dadanbekova D, Zhakipbekov K, Kodasbayev A, Datkhayev U, Petrova G, Tachkov K (2024) Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan. Pharmacia 71: 1–6. https://doi.org/10.3897/pharmacia.71.e115952
- Dattilo G, Bitto R, Correale M, Morabito C, Vaccaro V, Laterra G, Casale M, Crea P, DI Bella G, Luzza F, Migliorato A, Katsiki N, DE Gregorio C (2022) Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience. Minerva Cardiology and Angiology 70(5): 555–562. https://doi.org/10.23736/S2724-5683.20.05494-8
- Fazlollahi A, Zahmatyar M, Noori M, Nejadghaderi SA, Sullman MJM, Shekarriz-Foumani R, Kolahi AA, Singh K, Safiri S (2022) Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Reviews in Medical Virology 32(4): e2318. https://doi.org/10.1002/rmv.2318
- Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. Journal of the American College of Cardiology 35(5): 1245–1255. https://doi.org/10.1016/S0735-1097(00)00531-3
- Khaity A, Rababah AAM, Abdelwahab OA, Albakri K, Diab RA, Al-Dardery NM, Abbassy M, Al-Hanaqtah BM, Awad AK, Mohamad T (2023) Cardiovascular Disease and COVID-19 Vaccines: A Systematic Review and Analysis of Published Cases. European Cardiology 18: e54. https://doi.org/10.15420/ecr.2023.01
- Kornowski R, Witberg G (2022) Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination. Open Heart 9(1): e001957. https://doi.org/10.1136/openhrt-2021-001957
- Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K (2017) Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure 10(8): e003430. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430
- Mapelli M, Mattavelli I, Paolillo S, Salvioni E, Magrì D, Galotta A, De Martino F, Mantegazza V, Vignati C, Esposito I, Dell'Aversana S, Paolillo R, Capovilla T, Tamborini G, Nepitella AA, Filardi PP, Agostoni P (2023) Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration. European Journal of Clinical Pharmacology 79(9): 1173–1184. https://doi.org/10.1007/s00228-023-03527-y
- Omidi F, Hajikhani B, Kazemi SN, Tajbakhsh A, Riazi S, Mirsaeidi M, Ansari A, Ghanbari Boroujeni M, Khalili F, Hadadi S, Nasiri MJ (2021) COVID-19 and Cardiomyopathy: A Systematic Review. Frontiers in Cardiovascular Medicine 8: 695206. https://doi.org/10.3389/fcvm.2021.695206
- Pettersen KI, Reikvam A, Rollag A, Stavem K (2005) Reliability and validity of the Kansas City cardiomyopathy questionnaire in patients with previous myocardial infarction. European Journal of Heart Failure 7(2): 235–242. https://doi.org/10.1016/j.ejheart.2004.05.012
- Schreiber A, Elango K, Soussu C, Fakhra S, Asad S, Ahsan C (2022) COVID-19 Induced Cardiomyopathy Successfully Treated with Tocilizumab. Case Reports in Cardiology 2022: 9943937. https://doi.org/10.1155/2022/9943937
- Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA (2004) Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation 110(5): 546–551. https://doi.org/10.1161/01.CIR.0000136991.85540.A9
- Spertus JA, Jones PG, Kim J, Globe D (2008) Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients. Quality of Life Research 17(2): 291–298. https://doi.org/10.1007/s11136-007-9302-5
- Willi S, Lüthold R, Hunt A, Hänggi NV, Sejdiu D, Scaff C, Bender N, Staub K, Schlagenhauf P (2021) COVID-19 sequelae in adults aged less than 50 years: A systematic review. Travel Medicine and Infectious Disease 40: 101995. https://doi.org/10.1016/j.tmaid.2021.101995
- Yang HR, Xu XD, Shaikh AS, Zhou BT (2023) Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis. Annals of Pharmacotherapy 57(8): 907–917. https://doi.org/10.1177/10600280221140575